Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: Results from a double-blind oral combination study with glimepiride

Metabolism: Clinical and Experimental

Volumn 55, Issue 1, 2006, Pages 20-25

  Pfützner, Andreas ^a,b   Schöndorf, Thomas ^a   Seidel, Daniela ^c   Winkler, Karl ^d   Matthaei, Stephan ^e   Hamann, Andreas ^f   Forst, Thomas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c GLAXOSMITHKLINE   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Diabetes Center   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PROINSULIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PANCREATIC FUNCTION TESTS; PROINSULIN; PROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 28444495456     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.06.021     Document Type: Article

References (41)

1. S.V. Edelman The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors Rev Cardiovasc Med 4 2003 S29 S37
2. L. Olansky, A. Marchetti, and H. Lau Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels Clin Ther 25 2003 B64 B80
3. K. Hallsten, K.A. Virtanen, F. Lonnqvist, H. Sipila, A. Oksanen, and T. Viljanen Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes Diabetes 51 2002 3479 3485
4. A.B. Mayerson, R.S. Hundal, S. Dufour, V. Lebon, D. Befroy, and G.W. Cline The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 51 2002 797 802
5. Y. Miyazaki, L. Glass, C. Triplitt, M. Matsuda, K. Cusi, and A. Mahankali Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients Diabetologia 44 2001 2210 2219
6. B.H. Wolffenbuttel, R. Gomis, S. Squatrito, N.P. Jones, and R.N. Patwardhan Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients Diabet Med 17 2000 40 47
7. A. Hamann, S. Matthaei, H. Mauersberger, K. Thorn, N. Banik, and H.U. Haering Efficacy and safety of rosiglitazone in combination with glimepiride Diabetes Metab 29 2003 2288
8. A. Pfützner, A.H. Pfützner, M. Larbig, and T. Forst Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus Diabetes Technol Ther 6 2004 405 412
9. E.Z. Jia, Z.J. Yang, S.W. Chen, G.Y. Qi, C.F. You, and J.F. Ma Significant association of insulin and proinsulin with clustering of cardiovascular risk factors World J Gastroenterol 11 2005 149 153
10. B.J. Goldstein, and R. Scalia Adiponectin: a novel adipokine linking adipocytes and vascular function J Clin Endocrinol Metab 89 2004 2563 2568
11. M. Haluzik, J. Parizkova, and M.M. Haluzik Adiponectin and its role in the obesity-induced insulin resistance and related complications Physiol Res 53 2004 123 129
12. J.Y. Oh, E. Barrett-Connor, and N.M. Wedick Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study Circulation 105 2002 1311 1316
13. S.M. Haffner, and A.J. Hanley Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation 105 2002 2008 2009
14. J.S. Yudkin Increased proinsulin concentrations and excess risk of coronary heart disease in patients with diabetes and prediabetes Circulation 106 2002 e202
15. A. Pfützner, T. Kunt, A. Mondok, S. Pahler, T. Konrad, and G. Luebben Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes Diabetes Care 27 2004 682 687
16. A. Pfützner, A.H. Pfützner, P. Kann, R. Stute, M. Löbig, and J.W. Yang Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin Clin Lab 51 2005 734 738
17. K. Kubo Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes Endocr J 49 2002 323 328
18. A. Pfützner, C. Hohberg, G. Lübben, S. Pahler, A.H. Pfützner, and P. Kann Pioneer study: PPARγ-activation results in an overall improvement of clinical and metabolic markers associated with insulin resistance independent from long-term glucose control Horm Metab Res 37 2005 510 515
19. M. Ryo, T. Nakamura, S. Kihara, M. Kumadam, S. Shibazaki, and M. Takahashi Adiponectin as a biomarker of the metabolic syndrome Circ J 68 2004 975 981
20. S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, and Y. Nakajima Increased oxidative stress in obesity and its impact on metabolic syndrome J Clin Invest 114 2004 1752 1761
21. M.E. Trujillo, and P.E. Scherer Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome J Intern Med 257 2005 167 175
22. D.A. Garcia-Estevez, D. Araujo-Vilar, G. Fiestras-Janeiro, A. Saavedra-Gonzalez, and J. Cabezas-Cerrato Comparison of several insulin sensitivity indices derived from basal plasma insulin and glucose levels with minimal model indices Horm Metab Res 35 2003 13 17
23. B. Hedblad, P. Nilsson, L. Janzon, and G. Berglund Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden Diabet Med 17 2000 299 307
24. M. Matsubara, S. Maruoka, and S. Katayose Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women Eur J Endocrinol 147 2002 173 180
25. R. Nesto C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones Diabet Med 21 2004 810 817
26. A. Xu, L.C. Wong, Y. Wang, J.Y. Xu, G.J. Cooper, and K.S. Lam Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3-L1 adipocytes FEBS Lett 572 2004 129 134
27. S. Weldon, S. Mitchell, D. Kelleher, M.J. Gibney, and H.M. Roche Conjugated linoleic acid and atherosclerosis: no effect on molecular markers of cholesterol homeostasis in THP-1 macrophages Atherosclerosis 174 2004 261 273
28. B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, and I.P. Torra Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators Nature 393 1998 790 793
29. Y. Toriumi, M. Hiraoka, M. Watanabe, and M. Yoshida Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase FEBS Lett 553 2003 419 422
30. M. Stumvoll Thiazolidinediones-some recent developments Expert Opin Investig Drugs 12 2003 1179 1187
31. G. Chinetti, C. Zawadski, J.C. Fruchart, and B. Staels Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR Biochem Biophys Res Commun 314 2004 151 158
32. Z. Levi, A. Shaish, N. Yacov, H. Levkovitz, S. Trestman, and Y. Gerber Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model Diabetes Obes Metab 5 2003 45 50
33. N. Maeda, M. Takahashi, T. Funahashi, S. Kihara, H. Nishizawa, and K. Kishida PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2001 2094 2099
34. A. Pfützner, N. Marx, G. Lübben, M. Langenfeld, D. Walcher, and T. Konrad Improvement or cardiovascular risk markers by pioglitazone is independent from glycemic control-results from the Pioneer Study J Am Coll Cardiol 45 2005 1925 1931
35. M. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lübben, and T. Konrad Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with type 2 diabetes mellitus Circulation 111 2005 2525 2531
36. P. Mohanty, A. Aljada, H. Ghanim, D. Hofmeyer, D. Tripathy, and T. Syed Evidence for a potent antiinflammatory effect of rosiglitazone J Clin Endocrinol Metab 89 2004 2728 2735
37. M. Tiikkainen, A.M. Hakkinen, E. Korsheninnikova, T. Nyman, S. Makimattila, and H. Yki-Jarvinen Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2004 2169 2176
38. S.A. Smith, L.E. Porter, N. Biswas, and M.I. Freed Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes J Clin Endocrinol Metab 89 2004 6048 6053
39. H.C. Gerstein, S. Yusuf, R. Holman, J. Bosch, J. Pogue, and The DREAM Trial Investigators Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial Diabetologia 47 2004 1519 1527
40. B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, A. Skene PROactive Study Group The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 2004 1647 1653
41. C. Le Feuvre Cardiovascular effects of rosiglitazone Presse Med 33 2004 735 745